1. Introduction
Mycoplasma pneumoniae (
M. pneumoniae) is a major cause of community-acquired respiratory infections, particularly affecting children and young adults [
1]. Due to its lack of a cell wall,
M. pneumoniae is inherently resistant to a range of antibiotics that target cell wall synthesis. Although macrolides have traditionally served as the primary treatment option owing to their favorable tissue penetration and safety profile, macrolide-resistant
M. pneumoniae (MRMP) has become increasingly prevalent worldwide. This trend poses a substantial challenge to clinical management[
2]. Recent meta-analyses encompassing 27,408 clinical samples from 26 countries have identified concerning epidemiological trends, with resistance rates surpassing 50% in the Western Pacific region, thereby presenting a significant public health challenge [
3].
The principal mechanism underlying macrolide resistance is mainly attributed to target-site alterations in the 23S rRNA, notably the A2063G mutation, which is responsible for over 95% of
M. pneumoniae resistant strains by diminishing drug binding affinity[
4]. Additional mechanisms encompass mutations in ribosomal proteins L4 and L22, and, less frequently, the presence of efflux pumps or drug-modifying enzymes[
5,
6]. Although mutations in 2063 site constitute the primary mechanism of macrolide resistance in
M. pneumoniae, emerging clinical data suggest that other mechanisms may exist, particularly in pediatric populations[
7].
In our prior study, we performed genomic analysis of ten erythromycin-resistant
M. pneumoniae isolates[
6]. Notably, we identified recurrent mutations in macrolide specific efflux transporter, and efflux pump inhibitors caused a significant decrease of minimum inhibitory concentration (MIC), even restored susceptibility in some strains. These findings suggest that efflux pump mechanism contributes to macrolide resistance in
M. pneumoniae, alongside the well-documented point mutations in the 23S rRNA gene. In the present study, we focus on the role of a specific gene MPN080, which encodes the macrolide-specific efflux pump protein of the ATP-binding cassette (ABC) transporter family in
M. pneumoniae and shares some sequence similarity with the
MacB efflux pump gene in Escherichia coli. We aimed to characterize the genetic variations in
MPN080 and confirm their contribution to macrolide resistance phenotypes. This study is expected to yield critical insights into the mechanisms underlying treatment failure and inform strategies for combating resistant
M. pneumoniae infections.
2. Materials and Methods
2.1. Bacterial Strains and Culture Conditions
The M. pneumoniae strain M129 (ATCC 29342) and macrolide resistant clinical isolates (RC267) were cultivated in mycoplasma broth medium (HB7025-2, Haibo, Qiingdao Hope Bio-Technology Co., Ltd, China) ,which supplemented with 40% fetal bovine serum at 37°C. Antibiotic selection for plasmid transformed M. pneumoniae were performed using gentamicin at a concentration of 50 µg/ml. The bacterial cultures were monitored for changes in medium color, indicative of the logarithmic growth phase. E. coli TransT1 and BL21-CodonPlus(DE3)-RIL were used to clone and express the MPN_080 gene and were cultured in Luria-Bertani (LB) broth with antibiotics kanamycin (50 µg/ml) or gentamicin (100 µg/ml), respectively.
2.2. Phylogenetic Analysis
To investigate the evolutionary relationship of MPN_080 protein among different M. pneumoniae strains and its homologs, phylogenetic analysis was performed following standardized protocols. First, MPN_080 protein sequences from 14 M. pneumoniae strains (including the macrolide-resistant RC267, macrolide-sensitive M129, and 12 additional clinical isolates) were retrieved from the NCBI GenBank database. Homologous sequences of MPN_080 (ATPase proteins from related bacterial species) were also obtained via BLASTp search with M129 MPN_080 as the query sequence, and sequences with a similarity ≥70% and coverage ≥80% were selected for further analysis (accession numbers: WP_159202071.1, WP_058158331.1, WP_3MPN_08010166.1, WP_350260418.1, WP_017532940.1, WP_014325326.1, WP_019830476.1, WP_086136151.1, WP_054173838.1, WP_054175501.1, WP_054175921.1). All retrieved protein sequences were aligned using the MUSCLE algorithm implemented in MEGA11 software (version 11.0.13) with default parameters: gap opening penalty of 29, gap extension penalty of 0.2 for the first pass, and gap extension penalty of 0.1 for subsequent passes. The alignment quality was visually inspected and manually adjusted to eliminate ambiguous regions (e.g., regions with excessive gaps or low sequence conservation) to ensure the reliability of phylogenetic inference. A neighbor-joining (NJ) phylogenetic tree was constructed based on the multiple sequence alignment using MEGA11.
2.3. Expression and Purification of the M. pneumoniae MPN_080 protein
A codon-optimized MPN_080 gene from M. pneumoniae strain RC267 and M129 were synthesized by Sangon Biotech (Shanghai, China) and cloned into the pET-32a(+) vector. During synthesis, the eight tryptophan-encoding UGA codons naturally present in the gene were replaced with TGG to enable correct expression in E. coli. The resulting construct encodes a 1385-amino acid recombinant protein fused with a C-terminal His tag. The recombinant plasmid was then transformed into E. coli BL21-CodonPlus(DE3)-RIL competent cells. Protein expression was induced with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG, Invitrogen), then purified the expressed protein using a nickel-nitrilotriacetic acid (Ni-NTA) column according to the manufacturer’s instructions (Thermo Fisher Scientific, U.S.A.).
2.4. Vector Construction and Bacterial Transformation
The Strep-Tag II fragment was synthesized and amplified using PCR with specific primers(strepIIF:5’CACACACTAGTACGGATCCAGCCCATGGTGGAGC3’; strepIIR: 5’TCCTCTAGAAAAAGGCCATCCGTCAGGATGGCCTTCTTCTTTATTTTTCGAACTG3’). The purified PCR products were then fused to the linearized pMT85 vector, which had been digested with XbaI and BamHI at 37°C for 1 hour, using the Gibson Assembly cloning Kit (NEB, America). The assembled plasmids were introduced into Trans1 competent cells via heat shock. After transformation, the cells were plated on LB agar plates containing 100 µg/mL gentamicin and incubated at 37°C for 12–16 hours. Colonies were screened by colony PCR and sequenced to confirm the successful construction of the pMT85O vector. For the subsequent constructs, pMT85S (sensitive) and pMT85R (resistance), which referred the the MPN_080 gene fragment amplified from the M129 and RC267 genomic DNA using specific primers. The PCR products were then assembled into the linearized pMT85O vector backbone using the same Gibson Assembly method. Notably, these constructs incorporate the native promoter of the MPN_080 gene, which consists of a 235 bp upstream region immediately preceding the MPN_080 coding sequence. This region was included to ensure that the expression of the MPN_080 gene is regulated by its own promoter, maintaining the natural transcriptional control mechanisms in M. pneumoniae.
For the electrotransformation of M. pneumoniae M129, cultures in the late-logarithmic growth phase were collected and resuspended in Hepes-sucrose buffer to achieve a final concentration of 10⁹–10¹⁰ CCU/mL. A 200 μL aliquot of competent cells was combined with 100 μg of either the pMT85O or pMT85R or pMT85S plasmids. The mixture was incubated on ice for 5 minutes, followed by electroporation at 1.8 kV, 200 Ω, and 25 μF using a Bio-Rad Gene Pulser. Subsequent to electroporation, the cells were suspended in 1 mL of pre-warmed medium and incubated at 37°C for 1 hour to facilitate the expression of the antibiotic resistance marker. Transformants were selected on agar plates containing 50 μg/mL gentamicin. Individual colonies were subsequently transferred into mycoplasma broth medium supplemented with 40% fetal bovine serum and 50 μg/mL gentamicin. Positive clones were confirmed through PCR amplification (GNATF: GATACCAGTTCATTTGGGTT,GNATR: TGATCCATACCATAGACTATCTC ) and western blot.
2.5. Western Blot Analysis
Protein extracts were prepared from positive clones using RIPA lysis buffer supplemented with PMSF. Protein samples (10 µg per lane) were separated by 10% SDS-PAGE and transferred onto a PVDF membrane. The membrane was blocked with 5% skimmed milk in TBST and then incubated overnight at 4°C with an anti-Strep-tag II primary antibody (1:500 dilution, EnoGene E12-004-1). Following washing, the membrane was incubated with an HRP-conjugated goat anti-mouse secondary antibody (1:50,000 dilution, Boster BA1051) at 37°C for 2 h. Protein bands were visualized using an ECL substrate and imaged on a ChemiDoc system.
2.6. Minimum Inhibitory Concentration (MIC) Assays
Minimum inhibitory concentration (MIC) determinations were conducted in triplicate utilizing 96-well microtiter plates based on the Clinical and Laboratory Standards Institute (CLSI document M43A) completely[
8].
M. pneumoniae isolates, specifically wild-type M129 and M129-MPN_080 (overexpresseing MPN_080), were cultured in mycoplasma broth medium (HB7025-2, Haibo, Qiingdao Hope Bio-Technology Co., Ltd, China) supplemented with 40% fetal bovine serum at 37°C until the medium exhibited visible yellowing, indicative of logarithmic growth. Serial dilutions of antibiotics were made with final concentration of 128 μg/mL to 0.125 μg/mL;
M. pneumoniae suspensions were prepared in mycoplasma broth medium containing 10
5 CFU/mL. Negative controls comprised the strain inoculum without erythromycin. The plates were incubated at 37°C for a duration of 14 days, until the negative control exhibited a complete color change of the medium. MIC values were determined as the lowest concentration of the drug that completely inhibited visible growth, as evidenced by the absence of color change.
2.7. Infection of NCI-H292 Cells with MPN_080 Overexpression Mutants
NCI-H292 cells in the logarithmic growth phase were seeded at a density of 5×10⁵ cells per well in a 6-well plate and incubated overnight at 37°C with 5% CO₂. Mycoplasma strains were inoculated at a concentration of 10% (v/v) into 10 mL of mycoplasma broth supplemented with 10% bovine serum and cultured for approximately two weeks until a color change was observed. The culture was subsequently subjected to two-fold serial dilution to determine the color-changing unit (CCU) and adjusted to a concentration of 10⁸ CCU/mL. The prepared mycoplasma suspension was introduced at a multiplicity of infection (MOI) of 50:1, and the cells were incubated at 37°C with 5% CO₂ for 18 hours. After incubation, the medium was removed, and the cells were washed three times with phosphate-buffered saline (PBS) to remove unbound mycoplasma prior to performing Real-Time Quantitative PCR or electron microscopic analysisTransmission Electron Microscopy (TEM).
NCI-H292 cells underwent an initial fixation process in 2.5% glutaraldehyde dissolved in a 0.1M phosphate buffer (pH 7.4) at 4°C for a duration of 2 to 4 hours, followed by three washes with PBS. Subsequently, secondary fixation was conducted using 1% osmium tetroxide at ambient temperature for 2 hours, with subsequent washing. The dehydration process involved a graded ethanol series, and the samples were then infiltrated overnight with a mixture of acetone and 812 resin, followed by infiltration with pure resin overnight. The embedding was carried out at 60°C for 48 hours. Ultrathin sections, measuring 60–80 nm, were stained with 2% uranyl acetate and lead citrate, and allowed to dry overnight prior to transmission electron microscopy (TEM) observation.
2.8. PCR
DNA was isolated from infected NCI-H292 cells using the QIAamp Mini DNA kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Bacterial cells number was quantified by real-time PCR performed with the
M. pneumoniae MpP1 assay [
9].
2.9. Real-Time Quantitative PCR
Host gene expression analysis was analyzed by quantitative PCRs. Total RNA was isolated from cultured cells utilizing the Trizol method, followed by phase separation with chloroform and precipitation with isopropanol to obtain RNA. The purified RNA was quantified using a NanoDrop 2000 spectrophotometer, and its purity was evaluated based on the OD260/OD280 ratio. Reverse transcription into complementary DNA (cDNA) was conducted using HiScript III RT SuperMix, with genomic DNA being removed prior to the reverse transcription process. For quantitative PCR, a reaction volume of 10 µL per well was prepared in a 384-well plate, comprising 4 µL of cDNA, 1 µL of forward primer (10 µM), 1 µL of reverse primer (10 µM), 22.5 µL of SYBR Green Master Mix, and deionized water to reach a final volume of 45 µL before distribution into the reaction plate. The qPCR cycling conditions were set at 50°C for 2 minutes, 95°C for 5 minutes, followed by 40 cycles of 95°C for 15 seconds, 56°C for 20 seconds, and 72°C for 40 seconds. The primer sequences used were listed in
Table 1.
2.10. ATPase Activity Assay
The ATPase activity assay was performed using the EnzChek Phosphate Assay Kit (E6646, EnzChek) to quantify inorganic phosphate release according to the manufacturer's instructions. Activity was calculated as μmol Pi·μg⁻¹ protein based on triplicate measurements.
2.11. Statistical Analysis
The experimental data were subjected to statistical analysis utilizing GraphPad Prism version 8.0. The results are expressed as the mean ± standard deviation (mean ± SD). Comparative analysis between two groups was conducted using a two-tailed unpaired Student’s t-test. For comparisons across multiple groups, a one-way analysis of variance (ANOVA) was employed, followed by Tukey’s post hoc test for multiple comparisons. A P-value of less than 0.05 was considered indicative of statistical significance.
4. Discussion
M. pneumoniae is a significant etiological agent of community-acquired pneumonia, particularly among children and young adults, and contributes to a substantial burden of respiratory morbidity worldwide[
11]. Due to its high prevalence among pediatric populations and the limited use of alternative antibiotics in children, macrolide antibiotics have been used as the primary first-line therapeutic agents. Despite the relatively recent adoption of this treatment strategy, the resistance rate to macrolides has escalated rapidly[
12,
13,
14,
15,
16]. Notably, during the global pandemic of 2023-2024, resistance rates in certain regions of China have surged to as high as 99% [
17]. This poses a substantial public health challenge, prompting critical inquiries about whether novel mechanisms contribute to drug resistance, and whether these mechanisms can be exploited as therapeutic targets in the future.
Macrolide antibiotics exert their antibacterial effects by binding to the large subunit of the bacterial ribosome, thereby obstructing peptide chain elongation. They also disrupt proper ribosome assembly, ultimately inhibiting protein synthesis[
11]. The primary mechanism involves alterations in ribosomal targets, particularly mutations in the 23S rRNA gene—most notably at position A2063—which directly diminish antibiotic binding efficiency[
18] . Additionally, mutations in ribosomal proteins L4 and L22 can alter the conformation of the peptide exit tunnel, further impacting drug binding[
19]. Beyond these structural mechanisms, some pathogens express erm genes that encode rRNA methyltransferases, which modify rRNA and modify the drug-binding site[
20]. Streptococcus pneumoniae employ efflux systems encoded by mefA and mefE, which actively expel macrolides from the cell, thereby reducing their intracellular concentrations and effectiveness[
21]. Currently, only point mutations in the 23S rRNA gene and ribosomal proteins L4 and L22 genes have been reported in the resistance mechanism of
M. pneumoniae.
Our previous research showed that SNPs associated with macrolide resistant
M. penumoniae strains were focused on the
MacB gene, which belongs to macrolide-specific efflux system gene encoding a macrolide ABC transporter ATP-binding protein[
6], and the efflux pump inhibitors could decreases the MIC values. These findings demonstrate that an active efflux mechanism may lead to drug resistance of
M. pneumoniae to macrolide antibiotics.
In Gram-negative bacteria, MacB, a novel membrane transporter protein belonging to the bacterial ABC superfamily, together with MacA and TolC, formed a transmembrane complex that harnesses energy from ATP hydrolysis to transport a variety of biologically active molecules and polypeptide virulence factors from the cytoplasm, including macrolide antibiotics[
22]. In the case of
M. pneumoniae, we identified an ABC transpoter permease-mediated resistance pathway involving the ATPase MPN_080, which shares sequence homology and predicted structural features with the MacB protein, a membrane fusion component of the MacAB-TolC efflux pump in E. coli.
Through detailed functional analysis, we discovered two significant mutations (T752N and T1074I) in the ATPase MPN_080 in a strain with high-level erythromycin resistance. Functional tests confirmed that this mutated variant maintains ATPase activity and can increase erythromycin MIC by > 8 fold when overexpressed in susceptible strains. Meanwhile, overexpressing WT MPN_080 did not cause any changes in MIC values. These results indicated its role in efflux-mediated resistance mechanism beyond canical ribosomal pathways. ATPases, as crucial energy-converting enzymes on the cell membrane, are vital for maintaining membrane potential, ion balance, and transmembrane transport. Previous research has shown that changes in other mycoplasma membrane structure can significantly impact antibiotic translocation efficiency[
23]. Specifically, increased membrane lipid fluidity may alter membrane permeability, affecting antibiotic accumulation[
24]. Additionally, antibiotics like erythromycin and tetracycline not only inhibit protein synthesis but also enhance the membrane lipid fluidity of Chlamydia psittaci, causing conformational and functional changes in the membrane[
25].
Previous research has demonstrated that mutations in ATP-binding motifs, such as Walker A/B sites, can significantly enhance ATP hydrolysis efficiency, thereby augmenting efflux pump activity[
26]. Consequently, the mutations identified in MPN_080 in strain RC267 may enhance its ATPase activity, providing increased energy input to ABC transporters and improving drug efflux efficiency. Beyond drug efflux, surface-associated ATPases like OppA have been implicated in immune evasion and biofilm formation.
It is well-established that MUC5AC and MUC5B are the primary mucin components in respiratory mucus, playing crucial roles in maintaining the airway mucosal barrier and facilitating mucociliary clearance [
10]. In pediatric cases of
M. pneumoniae pneumonia, the pathogen may upregulate the expression of MUC5AC and MUC5B through the activation of the STAT6-STAT3 and epidermal growth factor receptor signaling pathways, leading to excessive mucus secretion and the formation of mucus plugs characteristic of plastic bronchitis[
27]. FOXA2, which functions as a transcriptional repressor, can bind to the promoter region of the MUC5AC gene and inhibit its transcriptional activity 27. Following infection with
M. pneumoniae, there is a significant downregulation of FOXA2 expression, resulting in the overexpression of MUC5AC and contributing to mucus hypersecretion27. In this study, despite the implications related to resistance, our colonization and host response assays revealed that the overexpression of MPN_080 did not impact bacterial adhesion to epithelial cells, nor did it significantly influence the expression levels of mucin-related genes (
MUC5AC and
MUC5B) or the transcription factor
FOXA2. The regulation of these host factors remained consistent across all infected groups, regardless of the expression levels of MPN_080.
In conclusion, this study identifies MPN_080 as a novel ATPase-dependent mediator of macrolide resistance in M. pneumoniae. The structural characterization of the transmembrane domains of MPN_080 provides a foundation for the development of targeted efflux inhibitors, while its mutation profile serves as a potential biomarker for clinical resistance screening. Beyond diagnostic applications, a detailed understanding of MPN_080's substrate specificity may facilitate the rational design of improved macrolide derivatives. Collectively, these findings significantly enhance our understanding of mycoplasma resistance mechanisms and present new opportunities for addressing the escalating challenge of antibiotic resistance.
Nonetheless, certain limitations were encountered in this study. Our efforts to identify interacting partners through pull-down experiments were unsuccessful. Possible reasons include transient or low affinity interactions, independent functioning of MPN 080 as a transmembrane transporter, the need for alternative experimental approaches to characterize its protein partners, or other factors. Another limitation of our study is that we only conducted validation experiments involving transformation on a drug-resistant strain, and more samples are required to further confirm the role of the efflux pump mechanism in M. pneumoniae resistance.